Literature DB >> 31512380

LTBP2 knockdown by siRNA reverses myocardial oxidative stress injury, fibrosis and remodelling during dilated cardiomyopathy.

Xue-Feng Pang1, Xue Lin2, Jian-Jun Du1, Ding-Yin Zeng1.   

Abstract

AIM: Dilated cardiomyopathy (DCM) is characterised by left ventricular dilation and associated with systolic dysfunction. Recent evidence has reported the high expression of latent transforming growth factor beta binding protein 2 (LTBP2) in heart diseases, which may play a role in regulating multiple biological functions of myocardial cells. Thus, this study set out to investigate the molecular mechanism and effects of LTBP2 in myocardial oxidative stress injury, fibrosis and remodelling in a rat model of DCM, with the involvement of NF-κB signalling pathway.
METHODS: The rat model of DCM was treated with si-LTBP2 and/or activator of NF-κB signalling pathway to examine the haemodynamic indexes, cardiac functions, oxidative stress injury, fibrosis and remodelling. Moreover, in vitro experiments were conducted to verify the regulatory role of LTBP2 and NF-κB signalling pathway in DCM.
RESULTS: LTBP2 was up-regulated in DCM rats. After LTBP2 was knocked down, haemodynamic indexes, HW/BW ratio, collagen volume fraction (CVF) level, positive expression of LTBP2, levels of reactive oxygen species (ROS), malondialdehyde (MDA), interleukin-6 (IL-6), tumour necrosis factor-alpha (TNF-α), tumour necrosis factor beta 1 (TGF-β1) and brain natriuretic peptide (BNP) were all decreased. Meanwhile, levels of LTBP2, Col-I, Col-III, p65 and p52 were also reduced, while HW, BW and levels of SOD and TAOC were increased. In contrast, activation of NF-κB signalling pathway reversed effects of LTBP2 gene silencing. These findings were confirmed by in vivo experiments.
CONCLUSIONS: LTBP2 silencing can attenuate myocardial oxidative stress injury, myocardial fibrosis and myocardial remodelling in DCM rats by down-regulating the NF-κB signalling pathway.
© 2019 Scandinavian Physiological Society. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  LTBP2; NF-κB signalling pathway; dilated cardiomyopathy; myocardial fibrosis; myocardial oxidative stress injury; myocardial remodelling

Mesh:

Substances:

Year:  2019        PMID: 31512380     DOI: 10.1111/apha.13377

Source DB:  PubMed          Journal:  Acta Physiol (Oxf)        ISSN: 1748-1708            Impact factor:   6.311


  6 in total

1.  Integrated microarray analysis to identify potential biomarkers and therapeutic targets in dilated cardiomyopathy.

Authors:  Hao Zhang; Junyu Huo; Wanying Jiang; Qijun Shan
Journal:  Mol Med Rep       Date:  2020-05-14       Impact factor: 2.952

2.  Latent Transforming Growth Factor-β Binding Protein-2 Regulates Lung Fibroblast-to-Myofibroblast Differentiation in Pulmonary Fibrosis via NF-κB Signaling.

Authors:  Menglin Zou; Jingfeng Zou; Xingxing Hu; Weishuai Zheng; Mingyang Zhang; Zhenshun Cheng
Journal:  Front Pharmacol       Date:  2021-12-24       Impact factor: 5.810

3.  Dissecting the cellular landscape and transcriptome network in viral myocarditis by single-cell RNA sequencing.

Authors:  Ninaad Lasrado; Nicholas Borcherding; Rajkumar Arumugam; Timothy K Starr; Jay Reddy
Journal:  iScience       Date:  2022-02-02

4.  Disruption of LTBP4 Inhibition-Induced TGFβ1 Activation Promoted Cell Proliferation and Metastasis in Skin Melanoma by Inhibiting the Activation of the Hippo-YAP1 Signaling Pathway.

Authors:  Lina Wang; Dongrun Tang; Tong Wu; Fengyuan Sun
Journal:  Front Cell Dev Biol       Date:  2022-02-17

5.  Transplantation of umbilical cord blood-derived mesenchymal stem cells as therapy for adriamycin induced-cardiomyopathy.

Authors:  Jingyue Zhang; Shiheng Zhang; Yueming Yang; Ling Liu
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

6.  LTBP2 inhibits prostate cancer progression and metastasis via the PI3K/AKT signaling pathway.

Authors:  Xiaowen Zhang; Chuanjie Tian; Jianbin Cheng; Weipu Mao; Menglan Li; Ming Chen
Journal:  Exp Ther Med       Date:  2022-07-08       Impact factor: 2.751

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.